Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Sectoral/ Thematic median (252 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 12 Mar 2026 – 20 Aug 2026, limited by ITI Business Cycle Fund. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | ITI Business Cycle Fund | Nifty 500 |
|---|---|---|
| 12 Mar 2026 | ₹100.00 | ₹100.00 |
| 25 Mar 2026 | ₹98.52 | ₹98.09 |
| 08 Apr 2026 | ₹100.22 | ₹101.09 |
| 21 Apr 2026 | ₹103.11 | ₹105.23 |
| 05 May 2026 | ₹104.06 | ₹104.16 |
| 18 May 2026 | ₹103.38 | ₹102.57 |
| 01 Jun 2026 | ₹102.72 | ₹102.47 |
| 14 Jun 2026 | ₹103.15 | ₹103.21 |
| 27 Jun 2026 | ₹104.61 | ₹105.55 |
| 11 Jul 2026 | ₹105.37 | ₹106.63 |
| 24 Jul 2026 | ₹102.93 | ₹104.64 |
| 07 Aug 2026 | ₹106.29 | ₹108.29 |
| 20 Aug 2026 | ₹106.73 | ₹107.38 |
| Metric | ITI · Direct NAV ₹10.65 Very High risk Unrated | Category median Sectoral/ Thematic · 252 funds |
|---|---|---|
| — | +7.23% | |
| — | +16.94% | |
| — | +14.70% | |
| — | +15.10% | |
| +6.73% | +14.07% | |
| +14.96% | — | |
| — | +17.59% | |
| — | +16.29% | |
| — | +16.00% | |
| Risk | ||
| 11.49% | 15.69% | |
| — | 0.52 | |
| — | 0.73 | |
| -4.28% | -23.08% | |
| Nifty 500 | — | |
| — | +4.66% | |
| — | 0.96 | |
| — | 109.1% | |
| — | 91.0% | |
| 1.76% | 1.14% | |
| ₹105.43Cr | ₹1,161Cr | |
| 0.50% | — | |
| None | — | |
| ₹500 | — | |
| ₹5.00K | — | |
| — | 45% | |
| Rajesh Bhatia | — | |
| 12 Mar 2026 | — | |
| 78 | — | |
| 22.6% | — | |
| 4.0% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.